1.90 - 2.15
0.48 - 2.54
9.88M / 2.92M (Avg.)
-0.48 | -4.19
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-48.94%
Cash & equivalents declining -48.94% while Drug Manufacturers - Specialty & Generic shows -2.59% growth. Howard Marks would investigate if this cash drain is temporary or signals deeper issues.
-1.64%
Short-term investments yoy growth below half the Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos would question if the firm lacks surplus cash or is facing liquidity stress.
-24.24%
Below half the Drug Manufacturers - Specialty & Generic median of 0.00% yoy growth. Jim Chanos might see inadequate liquidity buildup relative to peers. Verify free cash flow trends.
98.77%
Receivables growth above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see a serious red flag in ballooning receivables.
63.89%
Inventory growth above 1.5x Drug Manufacturers - Specialty & Generic median of 0.97%. Jim Chanos might see a red flag for potential obsolescence or poor planning.
416.48%
Exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might suspect questionable capitalization or one-time items inflating current assets.
-14.14%
Current assets growth ≥ 1.5x the Drug Manufacturers - Specialty & Generic median of -1.23%. Joel Greenblatt sees a potential liquidity edge if well allocated.
35.96%
PP&E growth below half of Drug Manufacturers - Specialty & Generic median of -0.21%. Jim Chanos would suspect potential underinvestment or strategic shift away from core assets.
6.72%
Goodwill growth above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see a red flag for future write-down risk or pricey takeovers.
-1.84%
Above 1.5x Drug Manufacturers - Specialty & Generic median of -0.90%. Jim Chanos warns of potential intangible bubble or over-capitalized R&D.
1.48%
Exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see big intangible expansions as a red flag for future impairments.
48.09%
≥ 1.5x the Drug Manufacturers - Specialty & Generic median of 0.00%. Joel Greenblatt sees a bigger push into long-term investments. Check synergy with core business.
-100.00%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos sees large expansions in deferred tax assets, possibly pointing to bigger NOLs.
845.11%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.07%. Jim Chanos sees a red flag for intangible or questionable expansions in the balance sheet.
45.95%
≥ 1.5x the Drug Manufacturers - Specialty & Generic median of 0.22%. Joel Greenblatt sees more aggressive long-term asset growth than peers, but it must be value-accretive.
-100.00%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos sees potential red flags in big "other" asset lumps.
11.84%
Below half the Drug Manufacturers - Specialty & Generic median of -0.02%. Jim Chanos might see potential stagnation or distress vs. peers.
-15.57%
Payables growth above 1.5x Drug Manufacturers - Specialty & Generic median of -4.40%. Jim Chanos might see a warning sign of stressed supplier payments.
3.39%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see a short-term leverage spike, raising red flags for near-term solvency.
No Data
No Data available this quarter, please select a different quarter.
-2.17%
Below half Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos sees a potential sales pipeline shortfall.
100.13%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos suspects a potential short-term burden spike.
-5.13%
Above 1.5x Drug Manufacturers - Specialty & Generic median of -2.62%. Jim Chanos suspects potential working capital strain.
5.29%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see a red flag for ballooning debt load.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos sees a potentially alarming surge in other LT obligations.
5.58%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos suspects a red flag in ballooning future obligations.
No Data
No Data available this quarter, please select a different quarter.
2.96%
Below half Drug Manufacturers - Specialty & Generic median of -0.80%. Joel Greenblatt sees a much lower liability expansion vs. peers.
6.91%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos suspects heavier share issuance than peers.
382.64%
Below half Drug Manufacturers - Specialty & Generic median of -0.40%. Jim Chanos suspects poor profitability or large dividend drains.
No Data
No Data available this quarter, please select a different quarter.
77.04%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos sees a potential red flag for complicated equity transactions.
13.20%
≥ 1.5x Drug Manufacturers - Specialty & Generic median of 0.57%. Joel Greenblatt sees stronger equity growth vs. peers.
11.84%
Below half Drug Manufacturers - Specialty & Generic median of -0.02%. Jim Chanos suspects a major slowdown or distress.
17.82%
≥ 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Joel Greenblatt sees bigger push into investments vs. peers.
5.20%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos suspects a big rise in leverage. Check coverage carefully.
87.88%
Above 1.5x Drug Manufacturers - Specialty & Generic median 6.38%. Jim Chanos sees a big jump in net debt. Potential leverage red flag.
